Adam R Craig has bought stock on 2 days since Aug 2022

Adam R. Craig, M.D., Ph.D., MBA, is an accomplished hematology/oncology executive currently serving as Executive Chairman and Board Chair of X4 Pharmaceuticals, Inc. (XFOR) on a part-time basis (approximately 24 hours per week), a role he assumed effective August 12, 2025, while also acting as the company’s Principal Executive Officer for SEC certifications.( Under his leadership, X4 executed two financings totaling $240.3 million in Q3 2025, announced a strategic shift prioritizing the 4WARD Phase 3 chronic neutropenia trial, and extended its cash runway to the end of 2028.(

Craig brings over 25 years of experience in hematology, oncology, and rare diseases drug development.( His prior roles include President and CEO of CTI BioPharma since March 2017, where he advanced candidates in blood-related cancers;( Chief Medical Officer and EVP of Development at Sunesis Pharmaceuticals (2012–2016); and CMO/SVP at Chemgenex Pharmaceuticals (2008–2012), which was acquired by Cephalon/Teva in 2011.( He currently serves as Interim CEO and Director at Stratus Therapeutics and Director at eGenesis.( Craig holds medical and bachelor's degrees from Charing Cross and Westminster Medical School, University of London; a Ph.D. in Molecular Oncology from Leeds University; an MBA from the Open Business School; and is a Member of the Royal College of Physicians (U.K.).(

Written by Perplexity from public sources.